<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Simon, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Chmiel, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2765019553"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pulmonary disease remains the leading cause of morbidity and mortality in people with cystic fibrosis (CF) [<a href="#rid1">1</a>]. Despite important advances in treatment, pulmonary exacerbations are a major driver of accelerated loss of lung function, decreased quality of life, and increased mortality [<a href="#rid2">2-5</a>].</p><p>Selection of antibiotics for pulmonary exacerbations is discussed below. An overview of pulmonary exacerbations is presented in a separate topic review, including clinical assessment, pathogenesis, interventions to promote secretion clearance, respiratory support, site of care, and the role of antiinflammatory and antiviral agents. (See  <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a>.)</p><p>Other aspects of pulmonary disease in CF are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">"Cystic fibrosis: Clinical manifestations of pulmonary disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p></p><p class="headingAnchor" id="H609949765"><span class="h1">RATIONALE FOR ANTIBIOTIC TREATMENT</span><span class="headingEndMark"> — </span>Systemic antibiotic treatment is indicated for all patients with acute pulmonary exacerbations and is recommended in virtually all consensus guidelines, in conjunction with a comprehensive regimen including promotion of airway clearance, continuation of modulator therapy (if eligible), optimization of nutrition, and management of CF-related diabetes (if present) [<a href="#rid6">6-9</a>]. Although antibiotic therapy is a nearly universal practice and reflects widespread expert opinion, it is based primarily on clinical experience and indirect evidence [<a href="#rid10">10</a>]. Pulmonary exacerbations are usually identified based on changes in symptoms and/or spirometry metrics, but the CF field has not reached a consensus definition. (See  <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations", section on 'Definition'</a>.)</p><p>The benefit of antibiotics for treating pulmonary exacerbations in patients infected with <em>Pseudomonas</em> <em>aeruginosa</em> has been evaluated in only a small number of placebo-controlled clinical trials [<a href="#rid11">11-14</a>]. All were published between 1980 and 1990, had fewer than 30 participants per study, and were of poor quality by today's standards [<a href="#rid15">15</a>]. Some but not all reported improved outcomes in the groups receiving antipseudomonal antibiotics.</p><p>Indirect evidence of the value of antibiotic treatment for exacerbations comes from observational studies reporting that bacterial density (particularly for <em>P</em>. <em>aeruginosa</em>) is correlated with pulmonary symptoms [<a href="#rid16">16</a>] and that bacterial density and inflammatory markers decrease after antibiotic treatment of pulmonary exacerbations [<a href="#rid17">17</a>]. In a study of nearly 10,000 individuals who had an acute drop in forced expiratory volume in one second (FEV<sub>1</sub>) of ≥10 percent from baseline, those whose episodes were diagnosed as pulmonary exacerbations and treated with antibiotics were more likely to recover to ≥90 percent of their baseline FEV<sub>1</sub> values [<a href="#rid18">18</a>].</p><p>Given the scarcity of high-quality evidence regarding antibiotic therapy, most recommendations are based on expert opinion, resulting in considerable variation in antibiotic-prescribing practices among CF clinicians [<a href="#rid19">19</a>]. In an effort to standardize care, the CF community has adopted guidelines that will be described below. Some of these practices are being actively challenged and are being studied in clinical trials. Decisions regarding antibiotic use need to balance their potential benefits against the burdens of cost, time for administration, and risks of adverse drug reactions.</p><p class="headingAnchor" id="H461472553"><span class="h1">OUR APPROACH TO ANTIBIOTIC SELECTION</span><span class="headingEndMark"> — </span>We select antibiotics using an individualized approach, based on the following considerations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogens identified in respiratory secretion cultures</strong> – We generally select antibiotics to cover each pathogenic species identified in the patient's recent respiratory secretion cultures, as recommended by virtually all guidelines [<a href="#rid6">6,7,9</a>]. Commonly used antibiotic combinations are outlined in the table  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>). We select at least two antibiotics to cover <em>P</em>. <em>aeruginosa</em> infections, although this practice is being actively reassessed, and least one antibiotic to cover any other pathogenic gram-negative bacteria (including <em>Achromobacter</em> species, <em>Burkholderia</em> <em>cepacia</em> complex species, and <em>Stenotrophomonas</em> <em>maltophilia</em>) [<a href="#rid6">6,7,9</a>]. (See <a class="local">'Respiratory secretion cultures'</a> below and <a class="local">'Double coverage for P. aeruginosa'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic susceptibility testing</strong> – For most pathogens, we use the patient's most recent antibiotic susceptibility test results to select antibiotics. However, for <em>P</em>. <em>aeruginosa</em>, we select antibiotics empirically based on their established antipseudomonal properties, often prescribing the same regimen that successfully treated the previous pulmonary exacerbation, because antibiotic selection based solely on susceptibility testing of <em>P</em>. <em>aeruginosa</em> appears not to improve outcomes. It is not always possible to cover each pathogen identified in the patient's sputum or to cover some multidrug-resistant organisms. (See <a class="local">'Antibiotic susceptibility testing and its limitations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to previous exacerbations</strong> – We prescribe the same antibiotic regimen that was previously successful, as measured by changes in symptoms and pulmonary function tests, unless the bacterial species identified in respiratory secretions have changed since the last episode.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity of the exacerbation</strong> – For mild exacerbations, we often begin with an oral regimen. For moderate or severe exacerbations or if the response to the initial oral regimen is suboptimal, we use a regimen that usually includes antibiotics that require intravenous (IV) administration. (See <a class="local">'Severity of the exacerbation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other considerations include the patient's drug allergies (which are common), toxicity risks, and patient preferences. We generally do not use inhaled antibiotics as a substitute for systemic antibiotics to treat moderate or severe exacerbations. (See <a class="local">'Other patient-specific considerations'</a> below and <a class="local">'Inhaled antibiotics'</a> below.)</p><p></p><p>This individualized approach reflects the uncertain value of using susceptibility testing to guide antibiotic selection, particularly for <em>P</em>. <em>aeruginosa</em>. (See <a class="local">'Antibiotic susceptibility testing and its limitations'</a> below.)</p><p class="headingAnchor" id="H1712460544"><span class="h1">KEY CONSIDERATIONS</span></p><p class="headingAnchor" id="H2490591503"><span class="h2">Respiratory secretion cultures</span><span class="headingEndMark"> — </span>We suggest performing cultures of expectorated sputum or throat swabs for nonexpectorating patients at least every three months during routine clinic visits, consistent with guidelines from the Cystic Fibrosis Foundation [<a href="#rid6">6,8,20,21</a>] and other expert groups [<a href="#rid7">7,9,22</a>]. Because people with CF often carry the same bacteria for prolonged periods of time, recent cultures are reasonably predictive of the pathogens present in a subsequent pulmonary exacerbation.</p><p>If a routine culture has not been performed within the few weeks prior to the start of an exacerbation, we usually obtain one at that time (see  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Periodic surveillance cultures'</a>). However, we modify the initially selected regimen only if the new culture results identify a new bacterial species that is not covered by the original regimen. There is insufficient information to assess the value of performing bronchoalveolar lavage to obtain fluid for culture at the time of a pulmonary exacerbation. The procedure is performed rarely in adults and occasionally in children. (See <a class="local">'Response to a failing regimen'</a> below.)</p><p>We do not broaden antibiotic coverage to cover pathogens beyond those identified in culture, because this does not improve clinical outcomes [<a href="#rid23">23</a>] and may promote acquisition of multidrug-resistant bacteria such as methicillin-resistant <em>Staphylococcus</em> <em>aureus</em> (MRSA) and multidrug-resistant <em>P</em>. <em>aeruginosa</em> [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1597896746"><span class="h2">Double coverage for <i>P. aeruginosa</i></span><span class="headingEndMark"> — </span>For <em>P</em>. <em>aeruginosa</em>, it common practice to treat pulmonary exacerbations with least two antibiotics, consistent with multiple CF guidelines [<a href="#rid6">6,7,9</a>]. The rationale for double coverage is that chronic infection with this bacterium is associated with a more rapid decline in pulmonary status and on the assumption that double coverage will have synergistic effects and might delay the generation of antibiotic resistance. However, note that there is little evidence to support the benefits of double coverage for <em>P</em>. <em>aeruginosa</em>, as summarized in a systematic revie<em>w</em> [<a href="#rid25">25</a>], subsequent retrospective studies using registry data [<a href="#rid26">26</a>], and secondary analysis of data from the STOP2 trial [<a href="#rid27">27,28</a>]. Regarding antibiotic resistance, two trials found that double therapy was associated with a trend toward a decrease in the frequency of antibiotic resistance compared with monotherapy, but the meta-analysis did not detect a statistically significant difference [<a href="#rid25">25</a>]. Fortunately, a prospective randomized study is underway to explore the utility of double antipseudomonal coverage (specifically, adding <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> to an intravenous [IV] antipseudomonal beta-lactam; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05548283&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSyvj6Lm7txEqGiAZufYPacEWGaSAby4oAMl9DkOsOcF2A%3D%3D&amp;TOPIC_ID=140721" target="_blank">NCT05548283</a>).</p><p class="headingAnchor" id="H2218238325"><span class="h2">Antibiotic susceptibility testing and its limitations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical approach</strong> – For <em>P</em>. <em>aeruginosa</em>, we select antibiotics based on their established antipseudomonal properties, the patient's response to previous regimens, and toxicity considerations; we use antibiotic susceptibility testing as a minor consideration. For other bacteria (eg, <em>S</em>. <em>aureus</em>, <em>S</em>. <em>maltophilia</em> or <em>Achromobacter</em> species), we are continuing the traditional practice of selecting antibiotics based on susceptibility test results, pending further study.</p><p></p><p class="bulletIndent1">The traditional practice of using susceptibility test results to guide antibiotic selection for <em>P</em>. <em>aeruginosa</em> is not well supported by accumulating data and is being actively questioned, because of accumulating evidence that this practice does not improve outcomes [<a href="#rid29">29-32</a>]. In a systematic review, susceptibility results failed to predict clinical response in 11 of 13 studies [<a href="#rid29">29</a>]. Among the two remaining studies, one study found a correlation for only of two treatment regimens being evaluated [<a href="#rid33">33</a>]. In the second study, multivariable logistic regression analysis showed that the correlation could be explained by imbalances in other risk factors known to influence treatment outcomes [<a href="#rid34">34</a>]. Finally, a subsequently published retrospective study of 2390 pulmonary exacerbations in 413 patients reported that improvements in forced expiratory volume in one second (FEV<sub>1</sub>) and body weight were no different between groups whose antibiotic selection fully covered, partially covered, or left uncovered the <em>P</em>. <em>aeruginosa</em> bacteria that were isolated [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1">This evidence has led some CF centers to decrease the frequency of routine antibiotic susceptibility testing to once a year for <em>P</em>. <em>aeruginosa</em> without apparent deleterious effect [<a href="#rid30">30</a>]. A group of experts was assembled by the Cystic Fibrosis Foundation to use a Delphi approach to generate a list of best clinical practices regarding selection of antibiotics [<a href="#rid22">22</a>]. No consensus could be reached regarding the use of antibiotic susceptibility test results to guide antibiotic selection for treatment <em>of</em> <em>P</em>. <em>aeruginosa</em> during acute exacerbations.</p><p></p><p class="bulletIndent1">There are multiple possible explanations for the problems with antibiotic susceptibility testing as performed in clinical microbiology laboratories, including inconsistent results on serial testing [<a href="#rid36">36</a>], variable results from specimens obtained from different airway segments [<a href="#rid37">37</a>], and differences in the properties of bacteria when grown under laboratory conditions compared with how they exist within CF airways conditions. Microbiome studies have demonstrated that the spectrum of bacteria present in the CF airway is much broader than what is identified by culture techniques [<a href="#rid38">38</a>]. The role of the previously unrecognized bacteria in pulmonary exacerbations is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternate strategies</strong> – To improve the utility of susceptibility testing, alternate strategies have been evaluated, but the results so far do not support their clinical use. One strategy is to culture bacteria under conditions that induce biofilm formation to mimic what occurs in the CF airway because bacteria grown in biofilms are generally less susceptible to antibiotics compared with bacteria grown under standard laboratory conditions [<a href="#rid39">39</a>]. However, clinical studies found no differences in patient outcomes or sputum bacterial density when antibiotic regimens were chosen based on susceptibility results from biofilms versus conventional cultures, as outlined in a systematic review [<a href="#rid40">40</a>]. Another strategy is to perform antibiotic synergy tests to determine if a multidrug-resistant isolate is susceptible to combinations of antibiotics, although they are resistant to each drug when tested separately [<a href="#rid41">41,42</a>]. Unfortunately, a large randomized trial showed no difference in clinical outcome when antibiotics were selected based on synergy testing compared with standard susceptibility testing [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coverage of multiple bacteria</strong> – It is not unusual for CF patients to have multiple bacterial species identified in their respiratory secretions. Selecting an antibiotic combination that covers all of the isolates is occasionally difficult without resorting to an impractically large number of antibiotics. Unfortunately, little information is available to determine the priority of the different pathogens when only a subgroup can be reasonably covered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anaerobic bacteria</strong> – The role of anaerobic bacteria in pulmonary exacerbations remains uncertain [<a href="#rid44">44</a>]. Although not detected in respiratory secretions using standard culture methods, anaerobic bacteria are commonly found in CF respiratory secretions by nonculture-based methods, with their relative abundance often increasing immediately prior to pulmonary exacerbations [<a href="#rid45">45</a>]. Nonetheless, a retrospective study of 514 pulmonary exacerbations in 182 subjects found that antibiotic coverage of anaerobic bacteria did not lead to better recovery of baseline of FEV<sub>1</sub> or prolong the time to the next exacerbation [<a href="#rid46">46</a>]. We therefore do not select antibiotics with the specific purpose to cover anaerobic bacteria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic-resistant bacteria</strong> – When in vitro testing can identify no antibiotic to which a bacterium is susceptible, our practice is to select from a list of antibiotics that would otherwise be chosen empirically for that pathogen  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>). Retrospective studies indicate that many patients will improve clinically under these circumstances [<a href="#rid29">29,31</a>]. Furthermore, the lack of correlation between susceptibility test results and clinical outcomes for <em>P</em>. <em>aeruginosa</em> indicate that clinicians should not be hesitant to choose antipseudomonal antibiotics that the laboratory reports as resistant.</p><p></p><p class="bulletIndent1">If a patient is clinically improving following initiation of antibiotics, we continue the regimen regardless of the resistance pattern reported from a sample obtained at the start of treatment. A retrospective study of 6451 pulmonary exacerbations in pediatric patients reported that antibiotic switching during treatment was more frequent when new susceptibility tests were performed but without evidence of improved outcomes [<a href="#rid47">47,48</a>].</p><p></p><p class="headingAnchor" id="H819468848"><span class="h2">Severity of the exacerbation</span><span class="headingEndMark"> — </span>The severity of an exacerbation is typically based on the clinician's global assessment of the change in symptoms compared with the patient's baseline. An exacerbation is usually considered severe if there are substantial changes in symptoms and/or &gt;10 percent decline in FEV<sub>1</sub> relative to the individual's baseline function. An exacerbation is mild if there are perceptible but small changes in symptoms or FEV<sub>1</sub> relative to baseline. (See  <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations", section on 'Severity grading'</a>.)</p><p>Antibiotic selection is partly influenced by the severity of the exacerbation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate or severe</strong> – A moderate or severe exacerbation generally warrants rapid initiation of aggressive therapy, under the assumption that doing so will increase the chances of returning to baseline status. <em>S</em>. <em>aureus</em> should be covered with a first-line drug (<a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, or <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>), and <em>P</em>. <em>aeruginosa</em> is typically covered with two systemic antibiotics  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>) (see <a class="local">'Our approach to antibiotic selection'</a> above). Aggressive treatment is warranted because the risk of permanent loss of lung function if the infection persists is thought to outweigh the risks of adverse effects from drug toxicity and the burden and complications of IV access.</p><p></p><p class="bulletIndent1">Note that the route by which an antibiotic is administered is determined by its bioavailability and should not be viewed as a reflection of its effectiveness. Many of the bacteria that infect CF airways require antibiotics that must be administered IV because they are not absorbed when given orally. However, certain orally administered antibiotics (<a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> and <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>) can be included in the regimen if appropriate to the patient's pathogens; they are effective because they are highly bioavailable and achieve therapeutic levels when administered orally.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild</strong> – For milder exacerbations, we agree with the common practice of using oral antibiotics to minimize the treatment burden and risk for adverse effects associated with IV treatment [<a href="#rid48">48-51</a>]. Evidence shows that this approach leads to clinical improvement [<a href="#rid50">50</a>], but the extent may not be as great compared with using more aggressive therapy such as regimens that include hospitalization and/or IV antibiotics [<a href="#rid18">18,52-54</a>]. If oral antibiotics are used, patients should be monitored closely and treatment escalated with consideration of hospitalization and/or using IV antibiotics if their inclusion better covers the bacteria identified by culture.</p><p></p><p class="bulletIndent1">For some individuals with mild exacerbations, an oral regimen may not be possible if they have resistant strains of bacteria (other than <em>P</em>. <em>aeruginosa</em>, for which antibiotic susceptibility testing has limited utility) or if they have drug allergy or intolerance. (See <a class="local">'Antibiotic susceptibility testing and its limitations'</a> above.)</p><p></p><p class="bulletIndent1">This practice of escalating to IV therapy for people who do not respond to oral antibiotics is supported by retrospective studies suggesting that oral antibiotics may be insufficient for some pulmonary exacerbations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one study, improvement in percent predicted FEV<sub>1</sub> a few days after treatment initiation was better in patients receiving IV antibiotics (5.1±12.7 standard deviation) compared with those receiving oral antibiotics only (2.0±11.6) [<a href="#rid49">49</a>]. However, FEV<sub>1</sub> measured during the 90 days after treatment did not differ between groups.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another study, patients who were treated with oral antibiotics alone had slower rates of FEV<sub>1</sub> improvement during treatment compared with those receiving regimens that included IV antibiotics [<a href="#rid54">54</a>]. Longer-term outcomes were not reported.</p><p></p><p class="bulletIndent1">Though provocative, these studies have limitations in that they are retrospective and subject to bias in treatment assignment that may not be adequately addressed by the statistical methods employed by the investigators.</p><p></p><p class="headingAnchor" id="H2602522611"><span class="h2">Other patient-specific considerations</span><span class="headingEndMark"> — </span>Although our antibiotic selection starts with the principles outlined above, other factors sometimes modify final choices based on an assessment of benefits versus risks:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug allergy and toxicity considerations</strong> – Allergies to antibiotics are common in patients with CF [<a href="#rid55">55</a>] and influence the choice among the antibiotic options suggested by the culture results [<a href="#rid55">55</a>]. If acceptable alternatives are not available, desensitization protocols can be used for antibiotics that previously caused immediate hypersensitivity reactions (see  <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">"Rapid drug desensitization for immediate hypersensitivity reactions"</a>). Any significant adverse effects that occurred during previous courses of antibiotics (eg, renal or ototoxicity from aminoglycosides) influence drug selection. (See <a class="local">'Aminoglycosides'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient preferences</strong> – Although the treatment options we present to a patient are derived from the above considerations, patient preferences can influence the final decisions. For example, some patients have strong opinions about when they are willing to use IV antibiotics or be hospitalized in given situations. After a discussion of the benefits and risks of the different options, we incorporate the patient's preferences when forming the treatment plan.</p><p></p><p class="headingAnchor" id="H2065208926"><span class="h2">Inhaled antibiotics</span><span class="headingEndMark"> — </span>In general, when a beta-lactam and/or either an aminoglycoside or colistimethate are indicated  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>), we deliver them parenterally and do not rely on their inhaled versions, although practice varies among clinicians [<a href="#rid49">49</a>]. (See <a class="local">'Dosing considerations for people with cystic fibrosis'</a> below.)</p><p>Evidence supporting our approach comes from a large registry study (9040 events in 3253 patients) in which the inclusion of an inhaled antibiotic did not improve outcomes, namely, increase in FEV<sub>1</sub> or time to next pulmonary exacerbation [<a href="#rid56">56</a>]. A previous systematic review found insufficient information from randomized trials to guide when to use inhaled antibiotics during exacerbations [<a href="#rid57">57</a>]. In addition, we suspect that inhaled antibiotics may be less effective because their distribution to the lungs of CF patients is known to be very inhomogeneous [<a href="#rid58">58</a>].</p><p>As exceptions, we might include an inhaled antibiotic in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span>For a relatively mild pulmonary exacerbation, when an inhaled antibiotic can be added to an oral medication (eg, a fluoroquinolone)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the inhaled antibiotic provides coverage for a particular bacterial isolate that is not otherwise covered by the chosen systemic regimen</p><p></p><p>If a patient's chronic baseline regimen includes an inhaled antibiotic (eg, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>), practice varies regarding whether to suspend the inhaled antibiotic until the course of IV antibiotics is complete. (See <a class="local">'Managing the chronically prescribed antibiotics'</a> below.)</p><p class="headingAnchor" id="H1857850829"><span class="h1">ANTIBIOTICS FOR SPECIFIC BACTERIA</span><span class="headingEndMark"> — </span>Typical antibiotic regimens for each of the common pathogens in people with CF are summarized in the table  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>) and discussed in more detail below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>P</em></strong><strong>. </strong><strong><em>aeruginosa</em></strong> – We select antibiotics from the list of those with known antipseudomonal activity and based on the patient's response to previous regimens and toxicity considerations. We use antibiotic susceptibility testing as a minor consideration. We generally select at least two antibiotics that cover this organism, although that approach is being called into question. (See <a class="local">'Antibiotic susceptibility testing and its limitations'</a> above and <a class="local">'Double coverage for P. aeruginosa'</a> above.)</p><p></p><p class="bulletIndent1">Appropriate options are  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For mild exacerbations, we treat with an oral fluoroquinolone, either <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, even if the clinical laboratory reports resistance, provided that the patient responded well in the recent past. Based on published pharmacokinetic studies, children with CF generally require higher doses of ciprofloxacin than other children (see <a class="local">'Ciprofloxacin'</a> below). For patients using an inhaled antipseudomonal antibiotic as part of their chronic treatment, we recommend that they continue the inhaled antibiotic or start a new course if they are in their "off" period.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For moderate or severe exacerbations, or if the above oral/inhaled regimen fails, we treat with an antibiotic combination that includes:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A beta-lactam – Such as <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> with cilastatin, or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (or ticarcillin-clavulanate, where available).</p><p></p><p class="bulletIndent3"><strong>Plus</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Either a fluoroquinolone (eg, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>) or <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> if recent use of a fluoroquinolone has failed. We select tobramycin rather than <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> because tobramycin usually has greater in vitro activity again<em>st</em> <em>P</em>. <em>aeruginosa</em> [<a href="#rid59">59</a>] and lower risk of drug-induced kidney injury [<a href="#rid60">60</a>]. We use intravenous (IV) rather than inhaled tobramycin for this purpose. (See <a class="local">'Inhaled antibiotics'</a> above.)</p><p></p><p class="bulletIndent1">For patients with newly acquired <em>P</em>. <em>aeruginosa</em>, sputum cultures should be obtained following successful treatment of the exacerbation to determine if the <em>Pseudomonas</em> has been eradicated. If not, an "early eradication" protocol should be used. (See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Prevention and eradication'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methicillin-sensitive </strong><strong><em>S</em></strong><strong>. </strong><strong><em>aureus</em></strong><strong> (MSSA)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For mild exacerbations, we treat with <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, or <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> when in vitro testing shows susceptibility. Based on published pharmacokinetic studies, children with CF generally require higher doses of trimethoprim-sulfamethoxazole than other children. (See <a class="local">'Trimethoprim-sulfamethoxazole'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For moderate or severe exacerbations, or if the above oral regimen fails, we treat with <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a> or <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methicillin-resistant </strong><strong><em>S</em></strong><strong>. </strong><strong><em>aureus</em></strong><strong> (MRSA)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For mild exacerbations, we treat with <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, if in vitro testing shows susceptibility to these drugs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For moderate or severe exacerbations, or if the above oral regimen fails, we treat with oral <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, IV <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, or IV <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> [<a href="#rid61">61</a>]. Although linezolid is administered orally, it is highly effective because of its high bioavailability and achieves therapeutic levels. Retrospective studies comparing vancomycin with either linezolid or ceftaroline have reported no differences in outcome [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1">Of note, <em>S</em>. <em>aureus</em> resistance to macrolides is increasing in patients treated chronically with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, causing macrolides to be less reliable for the treatment of <em>S</em>. <em>aureus</em> infections [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>P</em></strong><strong>. </strong><strong><em>aeruginosa</em></strong><strong> with MSSA or MRSA</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For mild exacerbations, we treat with an oral fluoroquinolone (either <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>) for the <em>P</em>. <em>aeruginosa</em> <strong>plus</strong> a second oral antibiotic to cover the MSSA or MRSA, as detailed above.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For moderate or severe pulmonary exacerbations, or if the above oral regimen fails:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>When MSSA accompanies the <em>P</em>. <em>aeruginosa</em>, we treat with a combination that includes <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> with cilastatin, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, or ticarcillin-clavulanate (the latter is not available in the United States) <strong>plus</strong> one of the following: an oral fluoroquinolone or IV <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, or <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a>, as discussed above.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>When MRSA accompanies the <em>P</em>. <em>aeruginosa</em>, we treat with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> <strong>plus</strong> the same antibiotic combination as for <em>P</em>. <em>aeruginosa</em> alone (three antibiotics total). Although <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> has good activity against MRSA, it is not effective for <em>P</em>. <em>aeruginosa</em>. B<em>e</em>cause we usually include an antipseudomonal beta-lactam to treat pulmonary exacerbations involving <em>P</em>. <em>aeruginosa</em>, we try to avoid ceftaroline for the MRSA out of concern for using two beta-lactams simultaneously, but we will resort to using two beta-lactams if there are no better options.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>B</em></strong><strong>. </strong><strong><em>cepacia</em></strong><strong> complex</strong> – We attempt to treat <em>B</em>. <em>cepacia</em> complex species when present, guided by in vitro antibiotic susceptibility testing. However, this is not always possible because these bacteria (which includes <em>Burkholderia</em> <em>multivorans</em> and <em>Burkholderia</em> <em>cenocepacia</em>) are often highly resistant to multiple antibiotics. The problem of choosing an antibiotic for <em>B</em>. <em>cepacia</em> complex species is compounded by poor performance of clinical laboratory antibiotic susceptibility testing [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">Treatment options are often limited, but some isolates show susceptibility to <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, and/or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>. When no single antibiotic is effective, combinations of two or more antibiotics sometimes show in vitro susceptibility [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Burkholderia cepacia complex'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Achromobacter</em></strong> – We treat <em>Achromobacter</em> species if present because there is evidence that some isolates can be particularly inflammatory in nature and are associated with an increased rate of forced expiratory volume in one second (FEV<sub>1</sub>) deterioration, similar to that induced by <em>P</em>. <em>aeruginosa</em> [<a href="#rid66">66-68</a>]. Although outcome studies of antibiotics to target <em>Achromobacter</em> species in CF exacerbations are lacking, we recommend <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, or <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>S</em></strong><strong>. </strong><strong><em>maltophilia</em></strong> – We attempt to treat <em>S</em>. <em>maltophilia</em> when this organism is identified in patients with pulmonary exacerbations and especially for patients with a deteriorating clinical course in whom <em>S</em>. <em>maltophilia</em> is the only cultured pathogen.</p><p></p><p class="bulletIndent1">Based on in vitro antibiotic susceptibilities of clinical isolates, we recommend <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> as the primary antibiotic but recognize that resistance is increasing [<a href="#rid69">69</a>]. Alternative antibiotics are <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>/<a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, or aztreonam/<a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>.</p><p></p><p class="bulletIndent1">Although we generally include <em>S</em>. <em>maltophilia</em> coverage in our antibiotic selection, evidence is conflicting regarding the importance of treating this organism. <em>S</em>. <em>maltophilia</em> is often found in the presence of other CF pathogens and is more frequent in patients with advanced lung disease [<a href="#rid70">70-72</a>]. Moreover, in our clinical experience, we have seen occasional patients with deteriorating clinical course in whom <em>S</em>. <em>maltophilia</em> is the only cultured pathogen. On the other hand, two studies suggest that acquisition of <em>S</em>. <em>maltophilia</em> may not affect subsequent disease progression, because the rate of FEV<sub>1</sub> decrease following new acquisition of <em>S</em>. <em>maltophilia</em> was no different from matched control patients [<a href="#rid70">70,72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Aspergillus</em></strong><strong> and </strong><strong><em>Candida</em></strong> – The prevalence of <em>Aspergillus</em> species in respiratory secretions has been reported to be between 12 and 35 percent [<a href="#rid73">73,74</a>]. Although there remains conflicting information whether <em>Aspergillus</em> contributes to the progression of CF lung disease (see  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Aspergillus species'</a>), there is no definitive evidence that <em>Aspergillus</em> causes pulmonary exacerbations. As such, we do not initiate antifungal therapy for pulmonary exacerbations when <em>Aspergillus</em> is identified. <em>Candida</em> species, particularly <em>Candida</em> <em>albicans</em>, are also frequently identified in CF respiratory secretions. Similar to <em>Aspergillus</em>, the clinical significance of their presence is doubtful [<a href="#rid75">75</a>] and we do not treat them.</p><p></p><p class="headingAnchor" id="H594221323"><span class="h1">DOSING CONSIDERATIONS FOR PEOPLE WITH CYSTIC FIBROSIS</span><span class="headingEndMark"> — </span>Dosing recommendations for antibiotics are summarized in the table  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>) and detailed below. The pharmacokinetics of many antibiotics are different in people with CF compared with the general population [<a href="#rid76">76,77</a>]. People with CF typically require higher and/or more frequent dosing for hydrophilic drugs (such as penicillins, cephalosporins, and aminoglycosides) due to increased volume of distribution and total body clearance.</p><p class="headingAnchor" id="H3684919695"><span class="h2">Beta-lactams</span><span class="headingEndMark"> — </span>For most beta-lactam antibiotics, we suggest increased doses for people with CF, as shown in the table  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>).</p><p>This strategy recognizes that people with CF often require higher doses of these drugs to maintain tissue concentrations above the minimum inhibitory concentration (MIC) through much of the dosing interval. For many of these antibiotics, our suggested doses are consistent with a comprehensive review of antipseudomonal antibiotics in CF [<a href="#rid78">78</a>]. For a few of the antibiotics (<a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, and ticarcillin-clavulanate), the review recommends much higher doses for people with CF than are used for the general population. These are based primarily on pharmacokinetic/pharmacodynamic considerations, but clinical trial data for these very high doses are sparse [<a href="#rid79">79</a>]. Therefore, we suggest intermediate doses for these drugs, as shown in the table. Higher doses may be considered on a case-by-case basis.</p><p>Prolonged or continuous infusion of beta-lactam antibiotics is used by an increasing number of CF programs, based primarily on theoretical considerations and limited clinical data [<a href="#rid80">80</a>]. The rationale is that prolonged/continuous infusions can better maintain blood levels above the MIC of susceptible bacteria than repeated short-duration infusions (see  <a class="medical medical_review" href="/z/d/html/97446.html" rel="external">"Prolonged infusions of beta-lactam antibiotics"</a>). Pharmacokinetic modeling and blood level measurements in people with CF confirm that continuous infusions achieve more prolonged time above MIC than intermittent dosing [<a href="#rid77">77,79,81</a>]. Scant data are available to determine if prolonged/continuous infusion improves clinically relevant outcomes in CF exacerbations [<a href="#rid82">82</a>]. The largest reported clinical trial compared intermittent with continuous infusion of <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> [<a href="#rid33">33</a>]. This randomized crossover study enrolled 70 people with CF, but only 49 completed both arms of the trial. There was no difference in forced expiratory volume in one second (FEV<sub>1</sub>) improvement between infusion strategies using an intention-to-treat analysis, but the per-protocol analysis showed that continuous infusion increased percent predicted FEV<sub>1</sub> by 4 points more than the intermittent arm. A retrospective analysis of 22 patients treated with beta-lactam antibiotics for 43 pulmonary exacerbations reported that FEV<sub>1</sub> recovery was not better in the subgroup of patients whose antibiotic dosing met predefined pharmacokinetic targets [<a href="#rid83">83</a>]. However, of note, no studies have reported worse outcomes using prolonged/continuous infusion.</p><p class="headingAnchor" id="H1000163757"><span class="h2">Aminoglycosides</span><span class="headingEndMark"> — </span>Starting doses of aminoglycosides for people with CF are higher than recommended for the general population  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>) [<a href="#rid84">84</a>]. The dose and frequency from a previous course of treatment may be used initially if serum concentrations were in the target range and creatinine clearance is not substantially changed, but drug levels should still be monitored. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p>The bactericidal effect of aminoglycosides is concentration dependent, and they have a postantibiotic effect (ie, bacterial growth remains suppressed for several hours after the antibiotic level drops below the MIC) (see  <a class="medical medical_review" href="/z/d/html/483.html" rel="external">"Aminoglycosides"</a>). People with CF tend to require higher doses of aminoglycosides than the general population because of both increased volume of distribution and accelerated renal clearance rate [<a href="#rid85">85</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Once-daily dosing (if renal function is normal)</strong> – For people with CF and normal renal function, we suggest dosing aminoglycosides once daily (known as "consolidated dosing" or "extended-interval dosing"). This approach is consistent with the guidelines endorsed by the Cystic Fibrosis Foundation [<a href="#rid6">6</a>] and is supported by a few small clinical trials and a meta-analysis [<a href="#rid86">86</a>]. This practice has been adopted by the majority of CF centers, including pediatric programs [<a href="#rid87">87</a>]. The starting dose for <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> is 10 mg/kg/24 hours for children and adults without renal insufficiency  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>), although a higher dose of 13 mg/kg/24 hours has been suggested for children younger than five years of age based on pharmacokinetic modeling [<a href="#rid88">88</a>]. In patients with obesity, the initial mg/kg dose should be altered by using adjusted body weight, which is calculated as lean body weight plus 40 percent of body weight in excess of lean body weight [<a href="#rid89">89,90</a>]. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p></p><p class="bulletIndent1">In a meta-analysis of three trials (289 participants), patients treated with once-daily aminoglycoside dosing had similar improvements in pulmonary function compared with multiple-daily dosing (difference in mean change in FEV<sub>1</sub> 0.3 percent, 95% CI -2.8 to 3.5) [<a href="#rid86">86</a>]. Once-daily therapy was associated with a lower risk of nephrotoxicity among pediatric patients (mean percent change in creatinine 8.2 percent lower, 95% CI 1.1-15.3), while the difference was not statistically significant in adult patients (mean difference 3.2 percent higher, 95% CI -1.8 to 8.3). The incidence of ototoxicity was low in both groups (0.4 versus 0.8 percent; relative risk 0.56, 95% CI 0.04-8.0). Of note, most of the patients enrolled in these trials were ≥5 years of age.</p><p></p><p class="bulletIndent1">Extended-interval dosing in populations without CF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides", section on 'Comparing extended-interval and traditional intermittent dosing'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial dose adjustment</strong> – We do not use published tables or nomograms for selecting and adjusting aminoglycoside doses and intervals in patients with CF, because the pharmacokinetics differ from those in non-CF patients and may result in suboptimal aminoglycoside concentrations [<a href="#rid91">91,92</a>].</p><p></p><p class="bulletIndent2">Instead, we measure serum levels twice following the first dose (eg, at 2 and 10 hours after the dose) and use pharmacokinetic analysis to calculate the peak serum level and to extrapolate forward to determine serum levels approximately 18 hours after the dose. Consultation with a clinical pharmacist skilled in pharmacokinetic-based drug management may be helpful and is suggested. The targets are:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Calculated peak serum level between 20 and 30 mcg/mL for <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> and between 80 and 120 mg/L for <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> [<a href="#rid78">78,93</a>]. Note that this is the estimated peak level calculated from a pharmacokinetic analysis and <strong>not</strong> the measured level from blood samples drawn early after antibiotic infusion. Samples taken less than two hours postinfusion are still within the drug distribution phase, so calculations based on them would yield incorrect estimates of peak antibiotic concentrations and clearance rates, leading to inappropriate dosing regimens [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Calculated serum level ≤0.5 mcg/mL at 18 hours, so that there is at least a six-hour period prior to the next dose when the patient will have low serum levels, to minimize toxicity. Slightly higher 18-hour levels (eg, ≤1.0 mcg/mL) are also acceptable, provided that the patient's renal function and clinical status are stable and the 18-hour level will be rechecked within three to four days.</p><p></p><p class="bulletIndent2">If a dose that achieves the target peak level leads to too high a serum level at 18 hours, the dosing strategy is changed to the "conventional" approach to reduce the risk of toxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent monitoring and dose adjustment</strong> – After the initial dose has been established, we measure serum aminoglycoside levels once or twice per week, with each measurement timed for several hours prior to the next dose (ie, at 18 hours following the previous dose). The appropriate frequency of monitoring depends on baseline renal function, the concomitant use of potentially renal toxic drugs, and whether the patient has a history of prior aminoglycoside toxicity. The goal is to ensure that the aminoglycoside level remains relatively low for several hours prior to the next dose (ideally ≤0.5 for <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> at 18 hours). An increasing 18-hour level suggests the possibility of renal injury and should prompt dose adjustment. We believe that the 18-hour time point is preferable to a true trough at 24 hours because in CF patients with normal renal function, the drug concentration is frequently below the level of detection at 24 hours, which would prevent early detection of renal impairment, as manifested by increasing drug levels. Interpreting these low serum levels can be confounded if the patient is also receiving inhaled tobramycin. As an example, serum levels one hour after inhaling 300 mg tobramycin are 1.05±0.67 mcg/mL (mean±standard deviation) [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent2">In addition, we suggest measuring two levels (eg, at 2 and 10 hours after the dose) following any substantial change in dose to allow pharmacokinetic calculations and assure that targeted levels are achieved. Two time point measurements are also recommended if large changes in volume of distribution are likely to have occurred during the course of treatment (eg, sepsis with capillary leak or right-sided heart failure), although these scenarios are uncommon in CF patients having a typical pulmonary exacerbation [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conventional dosing (for selected patients)</strong> – For patients with renal insufficiency or evidence of delayed aminoglycoside clearance, we do not use once-daily dosing for aminoglycosides. Instead, we use a conventional approach based on peak and trough levels to target drug levels, as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Peak serum concentration 8 to 12 mcg/mL for <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> or 20 to 30 mcg/mL for <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> (measured 30 to 45 minutes after the dose is given)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trough serum concentration ≤2 mcg/mL for <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> and &lt;10 mcg/mL for <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> (measured just before the next planned dose)</p><p></p><p class="bulletIndent1">These are the targets used for conventional dosing of aminoglycosides, but patients with renal insufficiency will require lower doses and/or longer dosing intervals than are used for patients with normal renal function.</p><p></p><p class="bulletIndent1">In this situation, the dose and frequency from a previous course of treatment may be used initially if the creatinine clearance is not substantially changed and serum concentrations were within the target range [<a href="#rid96">96</a>]. If there is no reliable historical information, we suggest consulting with an expert pharmacist to guide dosing with a pharmacokinetic analysis. If pharmacist consultation is not available, it is reasonable to use an empiric loading dose of 3.3 mg/kg (if the patient is overweight, use ideal body weight or dosing weight) [<a href="#rid6">6,93</a>] and select an initial maintenance dose and dosing interval based on the patient's creatinine clearance  (<a class="graphic graphic_table graphicRef57375" href="/z/d/graphic/57375.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">Once the initial dose and interval are established, we measure peak and trough levels once or twice per week and continue to adjust the dose and interval to ensure that target peak and trough concentrations are achieved and maintained. Blood urea nitrogen (BUN) and creatinine are measured at the same time to monitor for renal toxicity. These steps are detailed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminoglycoside toxicity</strong> – Individuals exposed to aminoglycosides require close monitoring to mitigate risk for renal injury and ototoxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring during treatment</strong> – Aminoglycoside levels should be monitored closely during treatment [<a href="#rid97">97-100</a>]. The timing and frequency of monitoring depends on whether a once-daily or conventional dosing strategy is used, as discussed above. In addition, BUN and creatinine levels should be measured whenever aminoglycoside serum levels are assessed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ongoing monitoring</strong> – We also suggest the following ongoing steps for people who are exposed to aminoglycosides:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serum magnesium - Measure serum magnesium levels periodically in patients who have received multiple aminoglycoside courses within the past year. These individuals are therefore at increased risk for isolated tubular damage, manifested by magnesium wasting.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hearing tests – Perform hearing tests, as recommended in a guideline from the Cystic Fibrosis Foundation [<a href="#rid101">101</a>]: as a baseline for all children and adults with CF, annually for those exposed to ototoxic medications (eg, aminoglycosides), and following each course of intravenous (IV) ototoxic medications for those with established hearing loss.</p><p></p><p class="bulletIndent2">When clinically significant renal damage or ototoxicity is noted, efforts should be made to minimize subsequent use of IV aminoglycosides [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevalence</strong> – Acute nephrotoxicity is common during aminoglycoside treatment for CF exacerbations [<a href="#rid98">98,102</a>]. For example, a retrospective study of 66 patients receiving &gt;5 courses of aminoglycosides reported that acute kidney injury, defined by the Kidney Disease: Improving Global Outcomes serum creatinine criteria, occurred during at least one course of treatment in 50 (76 percent), most of which were of mild severity [<a href="#rid102">102</a>]. The consequences of repeated courses of aminoglycosides on renal function is less certain. Some studies have shown a correlation between number of courses of IV aminoglycosides and chronic renal impairment [<a href="#rid97">97,103</a>], while others have not [<a href="#rid102">102,104</a>]. Some of the discrepancy may be that those studies that reported chronic renal impairment collected data from when patients were more likely to be treated with <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> rather than <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> and when multiple daily doses were used rather than once daily. Patients receiving multiple courses of aminoglycosides are also at risk for developing magnesium wasting without azotemia [<a href="#rid105">105</a>].</p><p></p><p class="bulletIndent2">Decreased auditory perception following a single course of IV <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> has been reported in patients with CF treated for a pulmonary exacerbation in two prospective observational studies [<a href="#rid106">106,107</a>]. Although the extent of hearing loss from a single course of IV aminoglycoside is generally small, the accumulative effects of multiple exposures can be quite large. A retrospective study of 165 patients at a single CF center reported that 38 percent of those receiving 1 to 10 courses of IV aminoglycoside had measurable hearing loss and 80 percent of those receiving &gt;10 courses [<a href="#rid108">108</a>]. Another retrospective study of 106 pediatric patients using audiometry to measure hearing acuity confirmed hearing loss in those receiving multiple courses of IV tobramycin, but the magnitude of hearing loss was considered clinically imperceptible [<a href="#rid109">109</a>].</p><p></p><p class="headingAnchor" id="H4063111878"><span class="h2">Colistin</span><span class="headingEndMark"> — </span>IV <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> (colistimethate sodium [CMS]) is a useful option for <em>P</em>. <em>aeruginosa</em> strains that fail to respond to aminoglycosides and fluoroquinolones. We usually use it in combination with a beta-lactam antibiotic. Renal toxicity occurs at a frequency similar to or less than that of <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT02918409&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiQ1B4ATbKF5ZgJV9PIikS5sVzt2wbE6wpogyQRJxlorgw%3D%3D&amp;TOPIC_ID=140721" target="_blank">NCT02918409</a>, unpublished results) [<a href="#rid110">110,111</a>]. We monitor renal function at least twice weekly during treatment. Colistin should not be used in combination with IV aminoglycosides, due to additive renal toxicities. Dose-related neurotoxicity manifesting as perioral and tongue tingling, paresthesia of the extremities, slurred speech, and vertigo/dizziness is relatively common and usually diminishes following dose reduction [<a href="#rid112">112</a>]. Colistin overdose can cause neuromuscular blockade.</p><p>There is potential for confusion when choosing drug doses due to variability in how the antibiotic is labeled [<a href="#rid113">113,114</a>]. Careful attention to the details of the licensed prescribing information is advised. In the United States, each vial of CMS is labeled as containing 150 mg of colistin-base activity (CBA), which is the equivalent of 4,500,000 international units (or 4.5 million units) of CMS. To convert, 1 mg CBA (United States product) = approximately 30,000 international units CMS (European Union product). We administer 2.5 to 5 mg/kg per day CBA (approximately 75,000 to 150,000 international units/kg per day CMS) divided into three doses to a maximum of 300 mg per day CBA (approximately 9,000,000 international units per day CMS)  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>). Patients with obesity should be dosed by ideal body weight. The dosing frequency of every eight hours is supported by studies in CF patients [<a href="#rid115">115</a>] but differs from the recommendations of a consensus guidelines panel that addressed <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> use in patients with severe infections but that excluded reviewing studies in people with CF [<a href="#rid116">116</a>].</p><p>Neurotoxicity, which appears to be dose related and transient, is a common adverse effect of systemic <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> therapy in people with CF, even among those treated with the moderate doses described above [<a href="#rid111">111</a>]. As a result, we do not use the higher doses (eg, up to 7 mg/kg per day CBA and/or maximum doses of 360 mg CBA per day) that are sometimes used for non-CF populations and that have been advocated by some authors for CF [<a href="#rid114">114,117</a>]. (See  <a class="medical medical_review" href="/z/d/html/486.html" rel="external">"Polymyxins: An overview"</a>.)</p><p>Consensus guidelines for non-CF patients recommend <a class="drug drug_general" data-topicid="9790" href="/z/d/drug information/9790.html" rel="external">polymyxin B</a> in preference over <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">colistin</a> to treat invasive infections, based on superior pharmacokinetic characteristics and decreased nephrotoxicity [<a href="#rid116">116</a>]. For people with CF, clinicians have been hesitant to switch to polymyxin B because of the limited pharmacodynamic/pharmacokinetic studies of polymyxin B in this population [<a href="#rid118">118,119</a>]. A study comparing polymyxin B with colistin in people with CF did not find less renal toxicity with polymyxin B [<a href="#rid117">117</a>]. Another study reported frequent neurotoxicity at polymyxin B doses recommended for non-CF patients [<a href="#rid119">119</a>].</p><p class="headingAnchor" id="H78562494"><span class="h2">Vancomycin</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dosing</strong> – We use the same <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> dose and target blood levels that are used for treating a serious pulmonary infection in people without CF because the pharmacokinetics of vancomycin are similar in people with CF compared with the general population [<a href="#rid120">120</a>].</p><p></p><p class="bulletIndent1">For individuals with normal renal function, we start with a weight-based dose of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> of 45 to 60 mg/kg per day in three divided doses (up to 4 g per day) for adults [<a href="#rid121">121</a>] and 60 mg/kg per day (up to 3.6 g per day) in three or four divided doses for children  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>). Higher doses may be needed in younger children [<a href="#rid122">122</a>]. Some CF centers use protocols that include loading doses for adult patients. (See  <a class="medical medical_review" href="/z/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections"</a>.)</p><p></p><p class="bulletIndent1">Of note, a beta-lactam other than <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> should be selected when being used in combination with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> to reduce the risk of renal toxicity [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose-adjustment strategies</strong> – There are two methods of therapeutic monitoring for <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>: trough-guided dosing and area under the curve (AUC)-guided dosing, which requires the assistance of a clinical pharmacist  (<a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">table 3</a>). Our preferred approach is the AUC method, but this may vary from facility to facility. AUC-guided dosing was endorsed in a consensus guideline published jointly by four professional infectious disease and pharmacist societies [<a href="#rid122">122,124,125</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Trough-directed dosing</strong> – Measuring trough levels has been the previous standard method for adjusting <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> dose and continues to be so if a clinical pharmacist is not available to perform the calculations for AUC monitoring or when renal function is rapidly changing. It is also the method preferred by some experts for vancomycin dosing in children [<a href="#rid124">124,125</a>]. We usually obtain vancomycin trough concentrations immediately before the third or fourth dose after initiating vancomycin or following a dose change. We aim to achieve trough concentrations of 15 to 20 mcg/mL for adults and 7 to 10 mcg/mL for children. In observational studies in children, trough concentrations ≥15 mcg/mL have been associated with increased risk of acute kidney injury and have not been associated with improved outcomes [<a href="#rid126">126-128</a>]. If trough levels are outside of the target range, the amount of vancomycin administered with each dose can be adjusted, which will proportionally alter trough levels and AUC. Alternatively, the interval between doses can be adjusted, ideally with input from a clinical pharmacist [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>AUC-guided dosing</strong> – In the AUC-guided approach, the <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> dose is adjusted based on the ratio of the AUC over 24 hours to the MIC (AUC/MIC) [<a href="#rid122">122</a>]. Clinical pharmacists can use software programs to estimate the AUC/MIC from two serum levels taken at the post-distributional peak (one to two hours after the end of infusion) and within 30 minutes prior to the next infusion. Monitoring should begin within 24 to 48 hours of initiation of treatment. The target AUC/MIC is 400 to 600, assuming a vancomycin MIC of 1 mg/L. Additional details of AUC-guided dosing for children are provided in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.idsociety.org%2Fpractice-guideline%2Fvancomycin%2F&amp;token=1jIv0tCrG79r68%2FYmELnvlmp0mP7K%2FrmIL7haohq7xZjfb4lYZFbZLKqleitPvJZNiWYt56hntBmD%2Bs0VQHiyQ%3D%3D&amp;TOPIC_ID=140721" target="_blank">consensus guideline</a> [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent2">Once the target dosing has been achieved and if renal function is stable, we monitor trough levels every 7 to 10 days. More frequent monitoring is indicated for patients with changing renal function.</p><p></p><p class="bulletIndent2">Evidence supporting AUC-guided dosing includes a retrospective study of people with CF (113 adults and 42 children) that compared the outcomes of those whose dose was guided by AUC with those guided by trough levels [<a href="#rid129">129</a>]. The proportion of adults whose FEV<sub>1</sub> returned to baseline was higher in those who had doses guided by AUC (86 percent) than those guided by trough (57 percent). The frequency of acute kidney injury did not differ between groups, but the small number of patients who had higher grades of kidney injury were all in the trough-guided group. (See  <a class="medical medical_review" href="/z/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections"</a>.)</p><p></p><p class="headingAnchor" id="H222501877"><span class="h2">Ciprofloxacin</span><span class="headingEndMark"> — </span>Among the fluoroquinolones, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> has the best in vitro activity against <em>P</em>. <em>aeruginosa</em>. The pharmacokinetics of ciprofloxacin in people with CF are more variable than in the general population and may be altered by disease severity, concurrent drug therapy, and patient age [<a href="#rid130">130-133</a>]. Children with CF generally require higher doses of ciprofloxacin than other children. As an example, in a group of children with CF treated for severe pulmonary infection, clearance of ciprofloxacin was two times higher than in children without CF [<a href="#rid130">130</a>]. Oral is preferred over IV administration because it is well absorbed, has lower cost, and is more convenient [<a href="#rid133">133</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For children with CF, we use oral <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> at a dose of 40 mg/kg per day (up to 2 g daily) divided every 12 hours instead of standard doses of ciprofloxacin [<a href="#rid132">132,134</a>]. Ciprofloxacin has high bioavailability and achieves therapeutic levels when administered orally. If IV administration is needed, the dose is 30 mg/kg per day (up to 1.2 g daily) in three divided doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For adults with CF, we use <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> at 750 mg by mouth twice daily as is recommended for non-CF patients with severe respiratory tract infections because the pharmacokinetics of ciprofloxacin in adults with CF appear to be similar to that of adults without CF [<a href="#rid135">135,136</a>]. Higher doses (eg, 1 g by mouth twice daily) may also be appropriate based on theoretical considerations of pharmacokinetics and the level of susceptibility of the bacteria [<a href="#rid131">131</a>].</p><p></p><p class="headingAnchor" id="H2585480369"><span class="h2">Trimethoprim-sulfamethoxazole</span><span class="headingEndMark"> — </span>For people with CF, we use doses of 160 mg <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> with 800 mg sulfamethoxazole, given three times daily (rather than twice daily, as is typical for the general population).</p><p>Although pharmacokinetic information regarding <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> in people with CF is very limited, we suggest this increased frequency of dosing, based on two studies in adolescences and adults with CF that found increased clearances of <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> and sulfamethoxazole in this population [<a href="#rid137">137,138</a>].</p><p class="headingAnchor" id="H226730914"><span class="h2">Managing the chronically prescribed antibiotics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic inhaled antibiotics</strong> – Although practice varies, we generally suspend inhaled antibiotics during the course of IV antibiotics for a pulmonary exacerbation. Moreover, we do not use an inhaled antibiotic as a substitute for one of the antipseudomonal antibiotics that are recommended in the table  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>). If both inhaled and IV <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> are used concurrently, the inhaled drug can cause a modest increase in serum levels, possibly interfering with pharmacokinetic analyses and causing errors in dosing [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled tobramycin'</a>.)</p><p></p><p class="bulletIndent1">There is no evidence that adding or continuing an inhaled antibiotic is beneficial for treating a pulmonary exacerbation. A guidelines committee of the Cystic Fibrosis Foundation could not reach a conclusion regarding the risks and benefits of administering the same antibiotic by both IV and inhaled routes [<a href="#rid6">6</a>]. A retrospective study completed after publication of the guidelines found no added benefit from adding inhaled antibiotics to an IV regimen [<a href="#rid56">56</a>]. (See <a class="local">'Inhaled antibiotics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic </strong><strong>azithromycin</strong> – We continue administering oral <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> during the acute exacerbation if it is a component of the chronic pulmonary regimen, with some important exceptions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We temporarily stop <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> if continuation might cause adverse interactions with the antibiotics added to treat the exacerbation (eg, risk for QTc prolongation when used with fluoroquinolones) but recognizing that the half-life of azithromycin is long.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the intended antibiotic regimen will include <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a> (inhaled or IV), it is unclear whether <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> should be suspended. Concern has arisen that patients with acute pulmonary exacerbations may respond less favorably to tobramycin if they are receiving chronic azithromycin therapy [<a href="#rid139">139,140</a>]. A proposed mechanism is the induction of bacterial efflux pumps by azithromycin that reduces bacterial tobramycin levels [<a href="#rid141">141</a>]. There is no consensus within the CF community on how to respond to this provocative, but as yet inconclusive, information [<a href="#rid142">142</a>]. Options include discontinuing chronic azithromycin for patients who are likely to be prescribed tobramycin in the near future, continuing azithromycin but selecting antibiotics other than tobramycin to treat pulmonary exacerbations, or continuing the current practice of prescribing both azithromycin and tobramycin while waiting for more definitive data. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with nontuberculous mycobacteria should not be given <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> as their only antimycobacterial antibiotic to limit development of antibiotic resistance to it. (See  <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'</a>.)</p><p></p><p class="headingAnchor" id="H2499376226"><span class="h1">ONGOING MANAGEMENT</span></p><p class="headingAnchor" id="H2815830197"><span class="h2">Duration of treatment</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous (IV) antibiotics</strong> – For most patients treated with IV antibiotics for a pulmonary exacerbation, we recommend that the duration of therapy be based on each patient's initial response to treatment and not by a predetermined treatment plan, as follows [<a href="#rid27">27</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the response to treatment is rapid (eg, ≥8 point improvement in forced expiratory volume in one second (FEV<sub>1</sub>) and improved symptoms within 7 to 10 days of starting antibiotics), stop antibiotics after 10 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the response is slower, complete a 14-day course of antibiotics</p><p></p><p class="bulletIndent1">A longer course of antibiotics may be warranted for patients requiring intensive care unit (ICU) care and those who experience an acute pulmonary exacerbation despite a recent course of IV antibiotics. In such patients, antibiotics are continued until symptom and FEV<sub>1</sub> improvement have plateaued; typical treatment duration is 14 to 21 days.</p><p></p><p class="bulletIndent1">Our suggested approach for IV treatment is supported by results from the STOP2 trial, a randomized study of 982 adult patients who were treated with IV antibiotics for a pulmonary exacerbation based on their CF clinicians' clinical assessment [<a href="#rid27">27</a>]. Patients were assessed on day 7 to 10 of treatment and were categorized as having an early "robust" response (ie, increase in FEV<sub>1</sub> by &gt;8 percent predicted and decease in the Chronic Respiratory Infection Symptom Score by &gt;11 points) or a slower response (ie, not meeting the definition of "robust" response). Early robust responders (n = 277) were randomly assigned to stop treatment after either 10 or 14 days; slower responders (n = 705) were randomized to stop treatment after either 14 or 21 days. Two weeks after completing treatment, patients who received shorter antibiotic courses had a similar rate of treatment failure compared with those who received longer courses (early robust responders 1.8 versus 3.7 percent; difference -1.9 percent, 95% CI -7.5 to 3.3; slower responders 4.5 percent versus 5.1 percent; difference -0.6 percent, 95% CI -5.0 to 2.7). In addition, there were no important between-group differences for FEV<sub>1</sub> change from baseline: Among early robust responders, the mean FEV<sub>1</sub> change was 12.8 percent in the 10-day group versus 13.4 percent in the 14-day group (difference -0.7 percent, 95% CI -3.3 to 2.0). Among slower responders, the mean FEV<sub>1</sub> change was 3.4 percent in the 14-day group versus 3.3 percent in the 21-day group (difference 0.1 percent, 95% CI -1.1 to 1.3). Finally, the improvements in symptom scores and incidence of drug-induced toxicity did not differ between treatment groups.</p><p></p><p class="bulletIndent1">Although this clinical trial did not include pediatric patients, it is reasonable to expect that a shorter course of IV antibiotics would result in similarly comparable outcomes in this population. Thus, we suggest using the same approach in both children and adults. This clinical trial also did not include patients who require ICU care and those who experience a CF exacerbation despite a recent course of IV antibiotics. A relatively long course of antibiotics (eg, 14 to 21 days) may be appropriate for such patients.</p><p></p><p class="bulletIndent1">These recommendations may represent a change in clinician prescribing habits and patient expectations at many CF centers. Our experience is that a small but significant number of patients with moderate to severe exacerbations who do not return to their baseline symptom level by 14 days strongly request prolongation of antibiotic treatment. However, the clinical evidence cited above suggests that extending treatment is unlikely to achieve additional benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antibiotics</strong> – Oral antibiotics are usually prescribed for 14 to 21 days [<a href="#rid48">48,51,143</a>]. It is uncertain whether the results of the STOP2 trial [<a href="#rid27">27</a>], which studied patients receiving IV antibiotics, most of whom had some time in hospital, can be extrapolated to patients receiving all oral regimens that are usually delivered at home. Response to outpatient treatment may be slower than inpatient treatment, where adequate rest, airway clearance therapy, nutrition, and on-time delivery of medications are likely better. (See  <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations", section on 'Home management of exacerbations'</a> and  <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations", section on 'Site of care'</a>.)</p><p></p><p>Prognosis after recovery from a pulmonary exacerbation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H1732960549"><span class="h2">Response to a failing regimen</span><span class="headingEndMark"> — </span>Lack of improvement during antibiotic treatment should prompt a reexamination for contributing factors such as an asthmatic component to the exacerbation or the presence of other pathogenic organisms, eg, a virus, fungus, or mycobacterium. If a culture obtained at beginning of treatment reveals a new bacterial species not covered by currently administered antibiotics such as methicillin-resistant <em>S</em>. <em>aureus</em> (MRSA), we change the antibiotic regimen to treat it. Although this is a common practice if a patient is not improving as expected, two observational studies did not detect benefits of switching antibiotics [<a href="#rid47">47,144</a>]. Data are not available to assess the utility of bronchoalveolar lavage to guide a change in antibiotics when a patient fails to meet treatment goals. The procedure is performed more frequently in pediatric than adult patients and is not without complications. However, with fewer patients producing sputum following introduction of highly effective modulator therapy, the role of bronchoalveolar lavage after a failed treatment course is worthy of consideration.</p><p>Of note, prolonging treatment beyond two weeks did not lead to better symptom outcome or FEV<sub>1</sub> recovery in a large, randomized clinical trial [<a href="#rid27">27</a>]. (See <a class="local">'Duration of treatment'</a> above.)</p><p class="headingAnchor" id="H2851589554"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109226.html" rel="external">"Society guideline links: Cystic fibrosis"</a>.)</p><p class="headingAnchor" id="H2001534011"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Antibiotic therapy plays a central role in managing acute pulmonary exacerbations in patients with cystic fibrosis (CF). This practice is based on extensive clinical experience and observations that bacterial density (particularly <em>Pseudomonas</em> <em>aeruginosa</em>) correlates with pulmonary symptoms and that bacterial density and inflammatory markers decrease with antibiotic treatment. (See <a class="local">'Rationale for antibiotic treatment'</a> above.)</p><p></p><p class="bulletIndent1">Other aspects of managing pulmonary exacerbations are discussed separately, including clinical assessment, interventions to promote secretion clearance, respiratory support, site of care (home, hospital, or intensive care), and the role of antiinflammatory and antiviral agents. (See  <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic selection</strong> – Usual practice is to select at least one antibiotic to cover each bacterial isolate that is cultured from respiratory secretions. Acceptable antibiotic choices for common pathogens are summarized in the table  (<a class="graphic graphic_table graphicRef59661" href="/z/d/graphic/59661.html" rel="external">table 1</a>). The choice is also influenced by the patient's response to prior regimens, severity of the exacerbation, and antibiotic susceptibility testing. (See <a class="local">'Our approach to antibiotic selection'</a> above.)</p><p></p><p class="bulletIndent1">For most patients, we suggest double rather than single antibiotic coverage for <em>P</em>. <em>aeruginosa</em> infections (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, this issue is actively being reexamined and this recommendation may change as more data become available. (See <a class="local">'Respiratory secretion cultures'</a> above and <a class="local">'Double coverage for P. aeruginosa'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Route of administration</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate to severe exacerbations – For patients with moderate to severe exacerbations (eg, substantial changes in symptoms and/or &gt;10 percent decline in forced expiratory volume in one second [FEV<sub>1</sub>] relative to the individual's baseline function), we suggest intravenous (IV) rather than oral or inhaled antibiotics unless a highly effective oral antibiotic such as <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> is available for the targeted pathogen(s) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Another exception is when an inhaled antibiotic provides coverage for a particular bacterial isolate not covered by the IV agent(s). If the chronic regimen includes an inhaled antibiotic (eg, <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a>), we generally suspend the inhaled antibiotic until the course of IV antibiotics is complete, although practice varies. (See <a class="local">'Severity of the exacerbation'</a> above and <a class="local">'Inhaled antibiotics'</a> above and <a class="local">'Managing the chronically prescribed antibiotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild exacerbations – For patients with mild pulmonary exacerbations, we suggest an oral antibiotic (eg, a fluoroquinolone) plus an inhaled antibiotic (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The exceptions are when the patient has a resistant strain of bacteria not susceptible to an oral agent and when the patient has an allergy or intolerance to the oral agent. (See <a class="local">'Severity of the exacerbation'</a> above and <a class="local">'Ciprofloxacin'</a> above and <a class="local">'Inhaled antibiotics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic dosing for people with CF</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The pharmacokinetics of many antibiotics differs in patients with CF compared with normal individuals. People with CF generally require larger and/or more frequent dosing for penicillins, cephalosporins, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and fluoroquinolones. (See <a class="local">'Dosing considerations for people with cystic fibrosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For aminoglycosides, starting doses should be larger than those recommended for individuals without CF, but dosing must be adjusted based on pharmacokinetic analysis of serum levels because of considerable interindividual variation in clearance rates. For CF patients with normal renal function, we suggest once-daily aminoglycoside dosing ("consolidated dosing") rather than conventional dosing and monitoring, with adjustments of dose and timing based on monitoring of drug levels (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Once-daily dosing has comparable efficacy with conventional dosing and monitoring but has advantages of possibly reducing the risk of nephrotoxicity and simplifying administration and monitoring. (See <a class="local">'Aminoglycosides'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic duration</strong> – We suggest that the duration of IV antibiotic therapy be based on the initial response to treatment, as follows (see <a class="local">'Duration of treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a rapid response to treatment (eg, ≥8 point improvement in FEV<sub>1</sub> and improved symptoms within 7 to 10 days of starting IV antibiotics), we suggest a 10-day course of antibiotics (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a slower response, we suggest a 14-day course of antibiotics (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>)</p><p></p><p class="bulletIndent1">A longer course of IV antibiotics may be warranted for patients requiring intensive care unit (ICU) care and those who experience a CF exacerbation despite a recent course of IV antibiotics. In such patients, antibiotics are continued until symptom and FEV<sub>1</sub> improvement have plateaued (typical duration is 14 to 21 days).</p><p></p><p class="bulletIndent1">For most patients treated with oral antibiotics, we suggest a 14- to 21-day treatment course (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), with escalation of therapy if clinical goals are not met.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Cystic Fibrosis Foundation. 2021 Patient Registry: Annual Data Report. Available at: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf (Accessed on November 10, 2022).</li><li><a class="nounderline abstract_t">Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166:1550.</a></li><li><a class="nounderline abstract_t">Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153:345.</a></li><li><a class="nounderline abstract_t">Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002; 121:64.</a></li><li><a class="nounderline abstract_t">Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134.</a></li><li><a class="nounderline abstract_t">Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180:802.</a></li><li><a class="nounderline abstract_t">Döring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16:749.</a></li><li><a class="nounderline abstract_t">Lahiri T, Hempstead SE, Brady C, et al. Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. Pediatrics 2016; 137.</a></li><li class="breakAll">Antibiotic treatment for cystic fibrosis. In: Report of the UK Cystic Fibrosis Trust Antibiotic Working Group, 3rd ed, 2009.</li><li><a class="nounderline abstract_t">Caverly LJ, VanDevanter DR. The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation. J Pediatric Infect Dis Soc 2022; 11:S40.</a></li><li><a class="nounderline abstract_t">Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141:914.</a></li><li><a class="nounderline abstract_t">Hyatt AC, Chipps BE, Kumor KM, et al. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1981; 99:307.</a></li><li><a class="nounderline abstract_t">Wientzen R, Prestidge CB, Kramer RI, et al. Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy. Am J Dis Child 1980; 134:1134.</a></li><li><a class="nounderline abstract_t">Gold R, Carpenter S, Heurter H, et al. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1987; 111:907.</a></li><li><a class="nounderline abstract_t">Hurley MN, Prayle AP, Flume P. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database Syst Rev 2015; :CD009730.</a></li><li><a class="nounderline abstract_t">Sagel SD, Gibson RL, Emerson J, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009; 154:183.</a></li><li><a class="nounderline abstract_t">Ordoñez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:1471.</a></li><li><a class="nounderline abstract_t">Morgan WJ, Wagener JS, Pasta DJ, et al. Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis. Ann Am Thorac Soc 2017; 14:937.</a></li><li><a class="nounderline abstract_t">Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011; 46:870.</a></li><li><a class="nounderline abstract_t">Saiman L, Siegel J, Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003; 31:S1.</a></li><li><a class="nounderline abstract_t">Cystic Fibrosis Foundation, Borowitz D, Robinson KA, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155:S73.</a></li><li><a class="nounderline abstract_t">Zemanick E, Burgel PR, Taccetti G, et al. Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros 2020; 19:370.</a></li><li><a class="nounderline abstract_t">Cogen JD, Faino AV, Onchiri F, et al. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without Pseudomonas aeruginosa. Ann Am Thorac Soc 2022; 19:1320.</a></li><li><a class="nounderline abstract_t">Cogen JD, Onchiri FM, Hamblett NM, et al. Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa. Clin Infect Dis 2021; 73:987.</a></li><li><a class="nounderline abstract_t">Holland P, Jahnke N. Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2021; 6:CD002007.</a></li><li><a class="nounderline abstract_t">Cogen JD, Faino AV, Onchiri F, et al. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Clin Infect Dis 2021; 73:1589.</a></li><li><a class="nounderline abstract_t">Goss CH, Heltshe SL, West NE, et al. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med 2021; 204:1295.</a></li><li><a class="nounderline abstract_t">VanDevanter DR, West NE, Sanders DB, et al. Antipseudomonal treatment decisions during CF exacerbation management. J Cyst Fibros 2022; 21:753.</a></li><li><a class="nounderline abstract_t">Somayaji R, Parkins MD, Shah A, et al. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J Cyst Fibros 2019; 18:236.</a></li><li><a class="nounderline abstract_t">Ponce MC, Svendsen E, Steed L, Flume PA. Impact of a Reduction in Susceptibility Testing for Pseudomonas aeruginosa in a Cystic Fibrosis Program. Am J Respir Crit Care Med 2020; 201:114.</a></li><li><a class="nounderline abstract_t">Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003; 123:1495.</a></li><li><a class="nounderline abstract_t">Hurley MN, Ariff AH, Bertenshaw C, et al. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J Cyst Fibros 2012; 11:288.</a></li><li><a class="nounderline abstract_t">Hubert D, Le Roux E, Lavrut T, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009; 53:3650.</a></li><li><a class="nounderline abstract_t">Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012; 141:485.</a></li><li><a class="nounderline abstract_t">VanDevanter DR, Heltshe SL, Hilliard JB, Konstan MW. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis. J Cyst Fibros 2021; 20:257.</a></li><li><a class="nounderline abstract_t">Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 55:921.</a></li><li><a class="nounderline abstract_t">Jorth P, Staudinger BJ, Wu X, et al. Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs. Cell Host Microbe 2015; 18:307.</a></li><li><a class="nounderline abstract_t">Huang YJ, LiPuma JJ. The Microbiome in Cystic Fibrosis. Clin Chest Med 2016; 37:59.</a></li><li><a class="nounderline abstract_t">Dales L, Ferris W, Vandemheen K, Aaron SD. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 2009; 28:1275.</a></li><li><a class="nounderline abstract_t">Smith S, Waters V, Jahnke N, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst Rev 2020; 6:CD009528.</a></li><li><a class="nounderline abstract_t">Lang BJ, Aaron SD, Ferris W, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000; 162:2241.</a></li><li><a class="nounderline abstract_t">Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161:1206.</a></li><li><a class="nounderline abstract_t">Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005; 366:463.</a></li><li><a class="nounderline abstract_t">Thornton CS, Caverly LJ, LiPuma JJ. Coming Up for Air: The Role of Anaerobes in Cystic Fibrosis. Ann Am Thorac Soc 2022; 19:713.</a></li><li><a class="nounderline abstract_t">Carmody LA, Caverly LJ, Foster BK, et al. Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. PLoS One 2018; 13:e0194060.</a></li><li><a class="nounderline abstract_t">Castner LM, Zimbric M, Cahalan S, et al. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria. J Cyst Fibros 2021; 20:926.</a></li><li><a class="nounderline abstract_t">Cogen JD, Whitlock KB, Gibson RL, et al. The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations. J Cyst Fibros 2019; 18:851.</a></li><li><a class="nounderline abstract_t">Stanojevic S, McDonald A, Waters V, et al. Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax 2017; 72:327.</a></li><li><a class="nounderline abstract_t">Wagener JS, Rasouliyan L, VanDevanter DR, et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2013; 48:666.</a></li><li><a class="nounderline abstract_t">Hoppe JE, Wagner BD, Accurso FJ, et al. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 2018; 17:760.</a></li><li><a class="nounderline abstract_t">Hoppe JE, Hinds DM, Colborg A, et al. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatr Pulmonol 2020; 55:3400.</a></li><li><a class="nounderline abstract_t">Bilton D, Canny G, Conway S, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 2011; 10 Suppl 2:S79.</a></li><li><a class="nounderline abstract_t">Schechter MS, VanDevanter DR, Pasta DJ, et al. Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. Ann Am Thorac Soc 2018; 15:225.</a></li><li><a class="nounderline abstract_t">VanDevanter EJ, Heltshe SL, Skalland M, et al. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis. J Cyst Fibros 2021; 20:932.</a></li><li><a class="nounderline abstract_t">Roehmel JF, Schwarz C, Mehl A, et al. Hypersensitivity to antibiotics in patients with cystic fibrosis. J Cyst Fibros 2014; 13:205.</a></li><li><a class="nounderline abstract_t">Cogen JD, Faino AV, Onchiri F, et al. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. Ann Am Thorac Soc 2020; 17:1590.</a></li><li><a class="nounderline abstract_t">Smith S, Rowbotham NJ, Charbek E. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 2022; 8:CD008319.</a></li><li><a class="nounderline abstract_t">Laube BL, Links JM, LaFrance ND, et al. Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients. Chest 1989; 95:822.</a></li><li><a class="nounderline abstract_t">Ekkelenkamp MB, Cantón R, Díez-Aguilar M, et al. Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Smyth A, Lewis S, Bertenshaw C, et al. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008; 63:532.</a></li><li><a class="nounderline abstract_t">Epps QJ, Epps KL, Young DC, Zobell JT. State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary. Pediatr Pulmonol 2021; 56:1825.</a></li><li><a class="nounderline abstract_t">Esquivel MD, Monogue ML, Smith GS, et al. Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adults. J Glob Antimicrob Resist 2022; 28:67.</a></li><li><a class="nounderline abstract_t">Fusco NM, Meaney CJ, Frederick CA, Prescott WA Jr. Comparative Effectiveness of Vancomycin Versus Linezolid for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis. Ann Pharmacother 2020; 54:197.</a></li><li><a class="nounderline abstract_t">Phaff SJ, Tiddens HA, Verbrugh HA, Ott A. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 2006; 57:741.</a></li><li><a class="nounderline abstract_t">Huse HK, Lee MJ, Wootton M, et al. Evaluation of Antimicrobial Susceptibility Testing Methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from Cystic Fibrosis Patients. J Clin Microbiol 2021; 59:e0144721.</a></li><li><a class="nounderline abstract_t">Hansen CR, Pressler T, Nielsen KG, et al. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros 2010; 9:51.</a></li><li><a class="nounderline abstract_t">Somayaji R, Stanojevic S, Tullis DE, et al. Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis. Ann Am Thorac Soc 2017; 14:1412.</a></li><li><a class="nounderline abstract_t">Kerem E, Orenti A, Zolin A, et al. Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis. J Cyst Fibros 2023; 22:334.</a></li><li><a class="nounderline abstract_t">Spencer HK, Spitznogle SL, Borjan J, Aitken SL. An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria. Pharmacotherapy 2020; 40:936.</a></li><li><a class="nounderline abstract_t">Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002; 166:356.</a></li><li><a class="nounderline abstract_t">Waters V, Yau Y, Prasad S, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011; 183:635.</a></li><li><a class="nounderline abstract_t">Berdah L, Taytard J, Leyronnas S, et al. Stenotrophomonas maltophilia: A marker of lung disease severity. Pediatr Pulmonol 2018; 53:426.</a></li><li><a class="nounderline abstract_t">Hong G, Psoter KJ, Jennings MT, et al. Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis. J Cyst Fibros 2018; 17:624.</a></li><li><a class="nounderline abstract_t">Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Mycol 2016; 54:781.</a></li><li><a class="nounderline abstract_t">Tracy MC, Moss RB. The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatr Pulmonol 2018; 53:S75.</a></li><li><a class="nounderline abstract_t">Castagnola E, Cangemi G, Mesini A, et al. Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review. Int J Antimicrob Agents 2021; 58:106381.</a></li><li><a class="nounderline abstract_t">Akkerman-Nijland AM, Akkerman OW, Grasmeijer F, et al. The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opin Drug Metab Toxicol 2021; 17:53.</a></li><li><a class="nounderline abstract_t">Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatr Pulmonol 2013; 48:525.</a></li><li><a class="nounderline abstract_t">Hong LT, Liou TG, Deka R, et al. Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis. Chest 2018; 154:1108.</a></li><li><a class="nounderline abstract_t">Zobell JT, Epps K, Kittell F, et al. Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach. J Pediatr Pharmacol Ther 2016; 21:239.</a></li><li><a class="nounderline abstract_t">Magréault S, Roy C, Launay M, et al. Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions. Clin Pharmacokinet 2021; 60:409.</a></li><li><a class="nounderline abstract_t">Prescott WA Jr, Gentile AE, Nagel JL, Pettit RS. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. P T 2011; 36:723.</a></li><li><a class="nounderline abstract_t">Hahn A, Burrell A, Chaney H, et al. Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis. Sci Rep 2023; 13:1217.</a></li><li><a class="nounderline abstract_t">Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health 2006; 42:601.</a></li><li><a class="nounderline abstract_t">Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol 2013; 48:1047.</a></li><li><a class="nounderline abstract_t">Bhatt J, Jahnke N, Smyth AR. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2019; 9:CD002009.</a></li><li><a class="nounderline abstract_t">Prescott WA Jr. National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther 2011; 16:262.</a></li><li><a class="nounderline abstract_t">Downes KJ, Grim A, Shanley L, et al. A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation. Antimicrob Agents Chemother 2022; 66:e0237721.</a></li><li><a class="nounderline abstract_t">Meng L, Mui E, Ha DR, et al. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update. Pharmacotherapy 2023; 43:226.</a></li><li><a class="nounderline abstract_t">Natale S, Bradley J, Nguyen WH, et al. Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. Pharmacotherapy 2017; 37:361.</a></li><li><a class="nounderline abstract_t">Coulthard KP, Peckham DG, Conway SP, et al. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations. J Cyst Fibros 2007; 6:125.</a></li><li><a class="nounderline abstract_t">Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. Br J Clin Pharmacol 2008; 65:502.</a></li><li><a class="nounderline abstract_t">Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Lancet 2005; 365:573.</a></li><li><a class="nounderline abstract_t">Aminimanizani A, Beringer PM, Kang J, et al. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 2002; 50:553.</a></li><li><a class="nounderline abstract_t">Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122:219.</a></li><li><a class="nounderline abstract_t">Bartel K, Habash T, Lugauer S, et al. Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring. Infection 1999; 27:268.</a></li><li><a class="nounderline abstract_t">Al-Aloul M, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39:15.</a></li><li><a class="nounderline abstract_t">Bertenshaw C, Watson AR, Lewis S, Smyth A. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007; 62:541.</a></li><li><a class="nounderline abstract_t">O'Donnell EP, Scarsi KK, Scheetz MH, et al. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. Int J Antimicrob Agents 2010; 36:94.</a></li><li><a class="nounderline abstract_t">Berg KH, Ryom L, Faurholt-Jepsen D, et al. Prevalence and characteristics of chronic kidney disease among Danish adults with cystic fibrosis. J Cyst Fibros 2018; 17:478.</a></li><li><a class="nounderline abstract_t">Kimple AJ, Senior BA, Naureckas ET, et al. Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations. Int Forum Allergy Rhinol 2022; 12:1089.</a></li><li><a class="nounderline abstract_t">Saad A, Young MR, Studtmann AE, et al. Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis. Pediatr Pulmonol 2020; 55:3384.</a></li><li><a class="nounderline abstract_t">Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother 1987; 31:594.</a></li><li><a class="nounderline abstract_t">Quon BS, Mayer-Hamblett N, Aitken ML, et al. Risk factors for chronic kidney disease in adults with cystic fibrosis. Am J Respir Crit Care Med 2011; 184:1147.</a></li><li><a class="nounderline abstract_t">Green CG, Doershuk CF, Stern RC. Symptomatic hypomagnesemia in cystic fibrosis. J Pediatr 1985; 107:425.</a></li><li><a class="nounderline abstract_t">Garinis A, Gleser M, Johns A, et al. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin. J Cyst Fibros 2021; 20:278.</a></li><li><a class="nounderline abstract_t">Harruff EE, Kil J, Ortiz MGT, et al. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. J Cyst Fibros 2021; 20:288.</a></li><li><a class="nounderline abstract_t">Zettner EM, Gleser MA. Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment. Otolaryngol Head Neck Surg 2018; 159:887.</a></li><li><a class="nounderline abstract_t">Madaule J, Valenzuela F, Mittaine M, et al. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis. J Cyst Fibros 2023; 22:944.</a></li><li><a class="nounderline abstract_t">Lipp MA, Crass RL, Fitzgerald LJ, et al. Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycin. J Antimicrob Chemother 2022; 77:2516.</a></li><li class="breakAll">ClinicalTrials.gov. IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy. 2023. Available at: https://clinicaltrials.gov/study/NCT02918409 (Accessed on July 19, 2023).</li><li class="breakAll">US Food and Drug Administration. Highlights of prescribing information for Coly-Mycin M Parenteral, 2009. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050108s026lbl.pdf (Accessed on April 30, 2023).</li><li><a class="nounderline abstract_t">Li J, Nation RL, Turnidge JD. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 2006; 50:4231; author reply 4231.</a></li><li><a class="nounderline abstract_t">Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010; 30:1279.</a></li><li><a class="nounderline abstract_t">Young DC, Zobell JT, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. Pediatr Pulmonol 2013; 48:1.</a></li><li><a class="nounderline abstract_t">Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39:10.</a></li><li><a class="nounderline abstract_t">Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41:645.</a></li><li><a class="nounderline abstract_t">Avedissian SN, Miglis C, Kubin CJ, et al. Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. Pharmacotherapy 2018; 38:730.</a></li><li><a class="nounderline abstract_t">Crass RL, Al Naimi T, Wen B, et al. Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis. Antimicrob Agents Chemother 2021; 65:e0079221.</a></li><li><a class="nounderline abstract_t">Pleasants RA, Michalets EL, Williams DM, et al. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother 1996; 40:186.</a></li><li><a class="nounderline abstract_t">Epps QJ, Epps KL, Young DC, Zobell JT. State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics. Pediatr Pulmonol 2020; 55:33.</a></li><li><a class="nounderline abstract_t">Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.</a></li><li><a class="nounderline abstract_t">LeCleir LK, Pettit RS. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients. Pediatr Pulmonol 2017; 52:1000.</a></li><li><a class="nounderline abstract_t">McNeil JC, Kaplan SL. Vancomycin Therapeutic Drug Monitoring in Children: New Recommendations, Similar Challenges. J Pediatr Pharmacol Ther 2020; 25:472.</a></li><li><a class="nounderline abstract_t">Regen RB, Schuman SS, Chhim RF, et al. Vancomycin Treatment Failure in Children With Methicillin-Resistant Staphylococcus aureus Bacteremia. J Pediatr Pharmacol Ther 2019; 24:312.</a></li><li><a class="nounderline abstract_t">McNeil JC, Kok EY, Forbes AR, et al. Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome. Pediatr Infect Dis J 2016; 35:263.</a></li><li><a class="nounderline abstract_t">Hahn A, Frenck RW Jr, Allen-Staat M, et al. Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia. Ther Drug Monit 2015; 37:619.</a></li><li><a class="nounderline abstract_t">McNeil JC, Kaplan SL, Vallejo JG. The Influence of the Route of Antibiotic Administration, Methicillin-Susceptibility, Vancomycin Duration and Serum Trough Concentration on Outcomes of Pediatric Staphylococcus aureus Bacteremic Osteoarticular Infection. Pediatr Infect Dis J 2016.</a></li><li><a class="nounderline abstract_t">Mitchell B, Kormelink L, Kuhn R, et al. Retrospective review of vancomycin monitoring via trough only versus two-point estimated area under the curve in pediatric and adult patients with cystic fibrosis. Pediatr Pulmonol 2023; 58:239.</a></li><li><a class="nounderline abstract_t">Payen S, Serreau R, Munck A, et al. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother 2003; 47:3170.</a></li><li><a class="nounderline abstract_t">Montgomery MJ, Beringer PM, Aminimanizani A, et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:3468.</a></li><li><a class="nounderline abstract_t">Schaefer HG, Stass H, Wedgwood J, et al. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother 1996; 40:29.</a></li><li><a class="nounderline abstract_t">Stockmann C, Sherwin CM, Zobell JT, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatr Pulmonol 2013; 48:211.</a></li><li><a class="nounderline abstract_t">Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemp Clin Trials 2009; 30:256.</a></li><li><a class="nounderline abstract_t">Christensson BA, Nilsson-Ehle I, Ljungberg B, et al. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1992; 36:2512.</a></li><li><a class="nounderline abstract_t">Steen HJ, Scott EM, Stevenson MI, et al. Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother 1989; 24:787.</a></li><li><a class="nounderline abstract_t">Reed MD, Stern RC, Bertino JS Jr, et al. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr 1984; 104:303.</a></li><li><a class="nounderline abstract_t">Hutabarat RM, Unadkat JD, Sahajwalla C, et al. Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. Clin Pharmacol Ther 1991; 49:402.</a></li><li><a class="nounderline abstract_t">Klingel M, Stanojevic S, Tullis E, et al. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis. Ann Am Thorac Soc 2019; 16:861.</a></li><li><a class="nounderline abstract_t">Somayaji R, Russell R, Cogen JD, et al. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. Ann Am Thorac Soc 2019; 16:853.</a></li><li><a class="nounderline abstract_t">Nichols DP, Happoldt CL, Bratcher PE, et al. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros 2017; 16:358.</a></li><li><a class="nounderline abstract_t">VanDevanter DR, LiPuma JJ. The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis. Ann Am Thorac Soc 2019; 16:819.</a></li><li><a class="nounderline abstract_t">Briggs EC, Nguyen T, Wall MA, MacDonald KD. Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience. Clin Respir J 2012; 6:56.</a></li><li><a class="nounderline abstract_t">Zikic A, Ratjen F, Shaw M, et al. The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations. J Cyst Fibros 2022; 21:759.</a></li></ol></div><div id="topicVersionRevision">Topic 140721 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cystic Fibrosis Foundation. 2021 Patient Registry: Annual Data Report. Available at: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf (Accessed on November 10, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406843" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207152" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Predictive 5-year survivorship model of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796433" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17643762" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19729669" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11106223" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27009033" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27009033" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36069900" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2109558" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7019407" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7004176" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3316565" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26226131" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18822427" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969869" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28324670" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21465675" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12762292" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914445" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31680041" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35289740" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33693586" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34159577" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34100912" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34469706" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35466039" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antipseudomonal treatment decisions during CF exacerbation management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30709744" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31469583" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Impact of a Reduction in Susceptibility Testing for Pseudomonas aeruginosa in a Cystic Fibrosis Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12740266" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22436723" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528265" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21835906" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32505525" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883175" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26299432" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26857768" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Microbiome in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19575248" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32520436" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11112146" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764313" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084254" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34936857" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Coming Up for Air: The Role of Anaerobes in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522532" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33612403" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31147301" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27539619" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22888106" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29921503" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32970375" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658647" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29140726" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33685776" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24169544" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hypersensitivity to antibiotics in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32726564" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35914011" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2924610" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31767727" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18245146" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Case-control study of acute renal failure in patients with cystic fibrosis in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33656280" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34936925" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ceftaroline versus vancomycin for treatment of acute pulmonary exacerbations of cystic fibrosis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31658825" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Comparative Effectiveness of Vancomycin Versus Linezolid for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16469851" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34524889" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Evaluation of Antimicrobial Susceptibility Testing Methods for Burkholderia cenocepacia and Burkholderia multivorans Isolates from Cystic Fibrosis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19939747" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28406714" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36418214" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32687670" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12153970" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20889901" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29314745" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Stenotrophomonas maltophilia: A marker of lung disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29444760" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27364649" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29992775" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The myriad challenges of respiratory fungal infection in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34157401" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33213220" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The pharmacokinetics of antibiotics in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23359557" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29908155" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27453702" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33486720" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22346306" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36681756" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16972966" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24000183" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31483853" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22768010" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35481751" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36703246" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Comprehensive guidance for antibiotic dosing in obese adults: 2022 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28079262" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16829216" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17995972" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708100" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12356801" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114362" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10885841" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15521084" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17234661" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Survey of acute renal failure in patients with cystic fibrosis in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20382508" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29187303" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Prevalence and characteristics of chronic kidney disease among Danish adults with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35089650" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32910553" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3606063" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799076" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Risk factors for chronic kidney disease in adults with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4032136" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Symptomatic hypomagnesemia in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32713806" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33341407" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29914288" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37088635" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35678460" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35678460" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35678460" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17122094" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114395" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22949160" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30710469" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11402633" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The pharmacokinetics of colistin in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29800496" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34252297" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8787903" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Pharmacokinetics of vancomycin in adult cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31609097" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32191793" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28440913" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32839650" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Vancomycin Therapeutic Drug Monitoring in Children: New Recommendations, Similar Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31337994" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Vancomycin Treatment Failure in Children With Methicillin-Resistant Staphylococcus aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646549" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26378371" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027279" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : The Influence of the Route of Antibiotic Administration, Methicillin-Susceptibility, Vancomycin Duration and Serum Trough Concentration on Outcomes of Pediatric Staphylococcus aureus Bacteremic Osteoarticular Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36203329" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Retrospective review of vancomycin monitoring via trough only versus two-point estimated area under the curve in pediatric and adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14506027" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11709326" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8787874" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22949224" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470318" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1489195" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2599998" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6607329" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2015729" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30874447" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30840835" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28025037" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35448933" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21595857" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35650003" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
